Discovery Labs Reports Encouraging Results for AEROSURF Phase 2a Clinical Program in Premature Infants 29-34 Weeks

By: via Benzinga
Discovery Laboratories, Inc. (NASDAQ: DSCO) today reported top line data from its recently completed AEROSURF® phase 2a clinical program ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.